프레드니솔론

용도

• Severe anterior uveitis
• Moderate to mild uveitis / Post-operative anterior segment surgery
• Feline IMHA Induction
• Severe anterior uveitis
• Moderate to mild uveitis / Post-operative anterior segment surgery
• Severe anterior uveitis
• Moderate to mild uveitis / Post-operative anterior segment surgery
• IMHA / IMTP Induction
• Steroid-responsive meningitis Induction

투여 방법

가능한 부작용

• Systemic absorption leading to iatrogenic hyperadrenocorticism (PU/PD/PP, panting, alopecia)
• Insulin resistance and destabilization of diabetes mellitus
• Delayed corneal healing
• Potentiation or exacerbation of ocular infections (bacterial, viral, fungal)
• Corneal degeneration or calcification (with long-term topical use)
• Hypothalamic-pituitary axis (HPA) suppression
• Adrenal atrophy
• Proteinuria and glomerular changes (dogs)
• Weight loss and muscle atrophy (catabolic effects)
• Iatrogenic hyperadrenocorticism (Cushing's syndrome)
• Vomiting and diarrhoea
• Gastrointestinal ulceration
• Hyperglycaemia

주의사항 및 금기

• Corneal ulcers (absolute contraindication for topical use)
• Ocular viral infections (e.g., Feline Herpesvirus-1)
• Ocular fungal infections
• Use with extreme caution in patients with uncontrolled diabetes mellitus or systemic infectious diseases
• Pregnant animals
• Renal disease (systemic use)
• Diabetes mellitus (systemic use)
• Ulcerative keratitis (topical ophthalmic use)
• Systemic fungal infections
• Concurrent NSAID administration
• Corneal ulcers
• > **Important Warning**: Subconjunctival and topical steroids can be absorbed systemically. Use with extreme caution in patients with endocrinopathies (e.g., diabetes mellitus) or infectious diseases. Even frequent topical steroid application in small animal patients under 20 kg can cause difficulties with diabetes mellitus regulation. Once the peak inflammatory response has been suppressed, consider transitioning to nonsteroidal anti-inflammatory drugs (NSAIDs) for ongoing maintenance treatment to minimize systemic steroid exposure.

약물 상호작용

• Topical NSAIDs (e.g., flurbiprofen, diclofenac): Concurrent use may increase the risk of delayed corneal healing or corneal melting, though sometimes used together cautiously for severe inflammation.
• Insulin: Systemically absorbed prednisolone antagonizes insulin, increasing blood glucose and complicating diabetes regulation.
• Systemic NSAIDs: Increased risk of gastrointestinal ulceration if significant systemic absorption of prednisolone occurs.
• NSAIDs: Increased risk of gastrointestinal ulceration
• Acetazolamide: Increased risk of hypokalaemia
• Amphotericin B: Increased risk of hypokalaemia
• Potassium-depleting diuretics (e.g., furosemide, thiazides): Increased risk of hypokalaemia
• Phenytoin: Enhanced metabolism of corticosteroids
• Phenobarbital: Enhanced metabolism of corticosteroids
• Itraconazole: Decreased metabolism of corticosteroids
• Ciclosporin: Synergistic immunosuppression; may alter pharmacokinetics

자주 묻는 질문